MEDP$568.53
Chart
Performance
Key Stats
AI MEDP Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
Strong BuyMedpace Holdings, Inc. demonstrates strong fundamental performance with consistent revenue and profit growth, supported by a healthy balance sheet. The company benefits from favorable industry trends in drug and medical device development. While technical indicators show a robust uptrend, some oscillators suggest potential for short-term overbought conditions. The thematic positioning in healthcare services is positive.
Thematic
Medpace is well-positioned within the growing clinical research organization (CRO) sector, driven by an aging global population, increasing R&D spending by pharmaceutical and biotech companies, and the growing complexity of drug development.
Fundamental
Medpace exhibits strong revenue and EPS growth, coupled with improving profit margins and a healthy balance sheet. The company has demonstrated consistent financial performance.
Technical
The stock is in a strong upward trend, with most moving averages indicating a buy signal. However, some oscillators are approaching or are in overbought territory, suggesting a potential for a short-term consolidation or minor pullback.
| Factor | Score |
|---|---|
| Healthcare R&D Spending | 85 |
| Aging Population & Chronic Diseases | 80 |
| Outsourcing Trend in Pharma/Biotech | 70 |
| Regulatory Landscape Complexity | 75 |
| Competition within CRO Market | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 85 |
| Growth | 80 |
| Balance Sheet Health | 95 |
| Cash Flow | 88 |
| Earnings Quality | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 60 |
| Volume Analysis | 75 |
| Support and Resistance | 70 |
| Analyst Ratings | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Earnings Surprises
The company has consistently beaten earnings per share (EPS) estimates for multiple quarters, with surprise percentages often exceeding 20% (e.g., 2025 Q2: 20.21%, 2025 Q1: 24.05%). This indicates robust operational execution and better-than-expected profitability.
Attractive Price-to-Sales Ratio Trend
The Price-to-Sales (P/S) ratio has shown a favorable trend, decreasing from 8.8 in 2022 to 5.4 in 2021 and then to 4.4 in 2024. While the TTM P/S is 5.7, the downward trajectory suggests increasing sales efficiency relative to market value, especially considering the recent revenue growth.
Bearish Points (7)
Elevated Quarterly P/E Ratios
While annual P/E ratios show some variability, quarterly P/E ratios are exceptionally high (e.g., 2025 Q2: 97.7, 2025 Q1: 74.7). This suggests that the market is pricing in significant future growth, making the stock vulnerable to corrections if growth expectations are not met.
Slowing Revenue Growth (QoQ)
Although annual revenue has grown, the quarterly revenue figures show a trend of deceleration from Q2 2024 ($528M) to Q3 2024 ($533M) and Q4 2024 ($536M), with a projected dip in Q1 2025 ($558M) and Q2 2025 ($603M). While Q2 2025 is a growth, the overall trend warrants attention.
Calendar
October 2025
21
Next Earnings Date
H: $3.66
A: $3.60
L: $3.45
H: 671.01M
A: 632.55M
L: 550.38M
Profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Seasonals
Price Target
385.28 USD
The 39 analysts offering 1 year price forecasts for MEDP have a max estimate of 490.00 and a min estimate of 297.34.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct and leading global competitor as a comprehensive contract research organization (CRO), offering end-to-end clinical and commercial solutions.
Weight: 95
Direct and major global competitor as a contract research organization (CRO), providing a full range of outsourced development services.
Weight: 90
Direct competitor, particularly strong in preclinical contract research and research models, a critical early stage in drug development.
Weight: 85
Direct competitor through its Covance segment, which is a major contract research organization (CRO) offering comprehensive clinical trial services.